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Abstract
Background: Population-based febrile respiratory illness surveillance conducted by the Department of Defense contributes
to an estimate of vaccine effectiveness. Between January and March 2011, 64 cases of 2009 A/H1N1 (pH1N1), including one
fatality, were confirmed in immunized recruits at Fort Jackson, South Carolina, suggesting insufficient efficacy for the pH1N1
component of the live attenuated influenza vaccine (LAIV).
Methodology/Principal Findings: To test serologic protection, serum samples were collected at least 30 days post-
vaccination from recruits at Fort Jackson (LAIV), Parris Island (LAIV and trivalent inactivated vaccine [TIV]) at Cape May, New
Jersey (TIV) and responses measured against pre-vaccination sera. A subset of 78 LAIV and 64 TIV sera pairs from recruits
who reported neither influenza vaccination in the prior year nor fever during training were tested by microneutralization
(MN) and hemagglutination inhibition (HI) assays. MN results demonstrated that seroconversion in paired sera was greater
in those who received TIV versus LAIV (74% and 37%). Additionally, the fold change associated with TIV vaccination was
significantly different between circulating (2011) versus the vaccine strain (2009) of pH1N1 viruses (ANOVA p
value=0.0006). HI analyses revealed similar trends. Surface plasmon resonance (SPR) analysis revealed that the quantity,
IgG/IgM ratios, and affinity of anti-HA antibodies were significantly greater in TIV vaccinees. Finally, sequence analysis of the
HA1 gene in concurrent circulating 2011 pH1N1 isolates from Fort Jackson exhibited modest amino acid divergence from
the vaccine strain.
Conclusions/Significance: Among military recruits in 2011, serum antibody response differed by vaccine type (LAIV vs. TIV)
and pH1N1 virus year (2009 vs. 2011). We hypothesize that antigen drift in circulating pH1N1 viruses contributed to reduce
vaccine effectiveness at Fort Jackson. Our findings have wider implications regarding vaccine protection from circulating
pH1N1 viruses in 2011–2012.
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Introduction
Crowded living quarters and stress can increase the potential for
respiratory infections among military service members and lead to
respiratory disease outbreaks [1,2,3,4]. Military members are
particularly susceptible to epidemics from seasonal or novel
influenza viruses, such as in 1918 when the rapid spread of A/
H1N1 among deploying troops and recruits resulted in an attack
rate estimated at 20% to 40% of U.S. Army and Navy personnel
[5]. In 1976, A/H1N1 ‘‘swine influenza’’ infections in soldiers
stationed at Fort Dix, New Jersey [6], drove fears of a pandemic
and recommendations of widespread vaccination of the U.S.
population [7]. The emergence of a quadruple reassorted A/
H1N1 virus (pH1N1) on the U.S.–Mexico border in 2009 [8,9,10]
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34581resulted in a pandemic that stressed medical capacity and
hampered military operations.
Since 1996, the Department of Defense (DoD) has conducted
population-based febrile respiratory illness (FRI) surveillance at
military recruit training centers (RTCs) across the United States
[11,12]. The DoD continually monitors influenza vaccine
effectiveness, one purpose of which is to elucidate factors
contributing to vaccine failure [13]. This representative sampling
of febrile recruits allows for an estimate of disease burden,
responsible pathogens, and pathogen subtypes. To counter
outbreaks of influenza, the trivalent inactivated vaccine (TIV)
has been used to protect military service members over the last 60
years [14]. Due to the ease of administration and often earlier
availability, the live attenuated influenza vaccine (LAIV) has been
preferentially utilized by the DoD since 2003 [15], especially
among recruit populations. Because military recruits are univer-
sally vaccinated prior to the first week of training, cases occurring
past the first 2 weeks of training, when vaccine-induced immunity
is established in a healthy population, may be an indication of
decreased vaccine effectiveness.
In the early months of 2011, FRI surveillance evidenced a sharp
rise in pH1N1 cases among LAIV-vaccinated recruits after the
second week of training at the U.S. Army RTC at Fort Jackson,
South Carolina, suggesting reduced effectiveness for the pH1N1
component [16]. During this outbreak, one vaccinated recruit was
hospitalized and died following laboratory-confirmed pH1N1
infection. To understand the contributing factors resulting in
increased rates of pH1N1, we undertook a serological study to
describe the corresponding antibody responses. Sera were drawn
4–5 weeks post-vaccination from recruits at Fort Jackson,
Columbia, South Carolina (Fort Jackson), Marine Corps Recruit
Depot, Parris Island, South Carolina (MCRD-PI), and Coast
Guard Training Center, Cape May, New Jersey (Cape May) in
March 2011. Microneutralization (MN) and hemagglutination
inhibition (HI) tests were conducted using standardized reagents in
the 2010–2011 World Health Organization (WHO) Influenza
Reagent Kit [17]. To study response to the 2011 circulating
pH1N1 strain, ferret antisera were generated from a pH1N1 virus
(A/CA/17/2011 H1N1) isolated from a recruit at Fort Jackson in
January 2011. Contemporaneous isolates from recruit training
sites across the United States were sequenced and analyzed for
divergence in the hemagglutination gene (HA). Herein we show
that the level and affinity of serum antibodies generated in
response to influenza vaccination in our population varied by
vaccine type (TIV vs. LAIV) and had significantly different
specificity to locally circulating pH1N1 viruses compared with the
vaccine strain. Decreased serologic response corresponded to
modest antigenic drift in the HA gene of pandemic A/H1N1
viruses circulating in the region in 2011.
Results
Influenza Vaccination, Sera Collection, and Study
Population Demographics
All recruits at Fort Jackson and male recruits at MCRD-PI
received the 2010–2011 LAIV, while female recruits at MCRD-PI
were vaccinated with TIV, as required by local protocol. At Cape
May, recruits were vaccinated with TIV.
Population-based FRI surveillance conducted between Decem-
ber 2010 and March 2011 noted laboratory-confirmed influenza
rates (per 100-person weeks) among influenza-vaccinated military
recruits at the three RTCs as: 0.15, Fort Jackson; 0.06, MCRD-PI;
and 0.05, Cape May. During this time, influenza A/H1N1 2009,
A/H3N2, and B viruses circulated in CDC region 4, with A/
H1N1 2009 virus predominating (Centers for Disease Control and
Prevention [CDC] FluView. 2010–2011 influenza season week 10;
http://www.cdc.gov/flu/weekly/weeklyarchives2010-2011/
weekly10.htm). Among 240 sampled FRI cases at Fort Jackson
between January and March of 2011, there were 64 pH1N1, 3 A/
H3N2 and 5 influenza B viruses determined by reverse
transcriptase polymerase chain reaction (RT-PCR) analysis.
Influenza infections continued at the study sites through March.
In this study, a total of 540 trainees were enrolled including 201
from Fort Jackson, 259 from MCRD-PI, and 80 from Cape May.
The average recruit numbers at the respective sites during this
period were 9000 at Fort Jackson, 4000 at MCRD–PI, and 550 at
Cape May. From 260 participants who reported no fever during
the preceding 4–5 weeks of basic training and no influenza
vaccination the previous year, a subset of 142 serum pairs were
selected for serologic testing. These included the first 50 enrollees
from Fort Jackson and MCRD-PI, and 42 from Cape May who
met the aforementioned criteria. Baseline sera were obtained from
the Department of Defense Serum Repository (DoDSR) in Silver
Spring, MD. Post-vaccination sera were compared with matched
baseline (pre-vaccination) samples drawn on average 133 days pre-
vaccination (range 2–498 days). The mean ages of study
participants were 22.1 years for the LAIV group and 20.9 years
for the TIV recruits (p=0.054). Sex varied, with 83% men in the
LAIV recipient group versus 59% men in the TIV group
(p=0.001). The mean days post-vaccination for sera used in the
study were 35.7 days in the LAIV group and 32.6 days in the TIV
group (p,0.0001).
Seroresponse as a Correlate of Microneutralization Titer
Samples from the three RTC sites were compared within TIV
and LAIV-vaccinated groups. Among the paired sera studied, 78
were from LAIV-vaccinated individuals and 64 from TIV-
vaccinated recruits. Madin-Darby canine kidney (MDCK) cell-
generated influenza viruses A/CA/7/2009 H1N1 (2009 pH1N1),
A/Perth/16/2009 H3N2 (H3N2), and A/CA/17/2011 H1N1
(2011 pH1N1) titered to a consistent concentration that gave 75%
cytopathic effect (CPE) were utilized in the MN assays.
The proportions of LAIV and TIV vaccinees for the range of
post-vaccination titers were plotted for the vaccine strain H3N2
and 2009 pH1N1 viruses and the circulating 2011 pH1N1 virus
(Figure 1). Overall, titers in TIV vaccinees were greater than
LAIV titers. Also, responses against the 2011 pH1N1 virus were
decreased compared with 2009 pH1N1 and H3N2 in both the
LAIV and TIV groups. Serologic responses in vaccinated recruits
following MN analysis are summarized in Tables 1 and 2. The
pre-vaccine geometric mean titer (GMT) levels among the groups
were not significantly different, although the percentage of
individuals with titers $40 was markedly higher in both 2009
pH1N1 and H3N2 groups likely because these viruses had
circulated for longer than the 2011 pH1N1 virus. More individuals
in both vaccine groups exhibited seroresponse against H3N2 than
the 2009 and 2011 pH1N1 viruses. Post-vaccine seroprotection
among LAIV vaccinees for 2009 pH1N1, H3N2, and 2011
pH1N1 was 51%, 62%, and 32%, while for TIV the percentages
were 73%, 97%, and 61%, respectively (Tables 1 and 2). Among
naı ¨ve subjects (those with initial titers #40), seroconversion was
greater among TIV than LAIV recipients for H3N2 (98% vs.
57%; p,0.0001), 2009 pH1N1 (74% vs. 43%; p=0.0007), and
2011 pH1N1 (64% vs. 30%; p,0.0001), and for any virus (77% vs.
43%; p,0.0001) (data not shown).
The baseline titer-adjusted fold change in MN titer associated
with TIV vaccination was significantly different between the 2011
and 2009 pH1N1 viruses. To illustrate these differences, we
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2011 and 2009 pH1N1 relative to conversion against the H3N2
strain (Figure 2). Results demonstrated that in TIV- and LAIV-
vaccinated recruits the adjusted odds of a 4-fold rise in titer were
sharply lower in the 2011 pH1N1 virus than the H3N2 virus
(analysis of variance (ANOVA) p=0.0006). Finally, while the
proportion of individuals with pre-vaccine serum antibody titers
($20) for all three viruses was higher by HA assays, the overall
trends were similar to those seen with the MN data.
TIV- and LAIV-Elicited 2009-pH1N1 HA1-Specific
Antibodies with Different Isotype Profiles and Binding
Avidity
Sera samples from a randomly selected subset of TIV (n=10)
and LAIV (n=18) vaccinees were analyzed by surface plasmon
resonance (SPR) for post-vaccination serum antibody binding to
properly folded, functional oligomeric recombinant HA1 peptide
against the 2009 pH1N1 strain. The maximum resonance unit
(max RU) values for the serum antibody binding antibodies to
rHA1 from LAIV (Figure 3A) and TIV (Figure 3B) vaccinated
groups strongly correlated with the MN titers against the pH1N1
vaccine strain A/CA/7/2009. Isotyping of post-vaccination
antibodies demonstrated that the majority (.90%) of the binding
to the HA1 globular domain (1–330 amino acids) in the TIV-
vaccinated individuals was mediated by IgG antibodies, with a
small contribution (#10%) from IgA antibodies irrespective of the
MN titers. In contrast, in the LAIV-vaccinated individuals, a
significant amount of rHA1 binding antibodies were IgM,
especially in sera with lower MN titers to 2009 pH1N1 (Figure 3C).
TIV-Vaccinated Individuals Show Better Antibody Affinity
Maturation to pH1N1 Compared with LAIV-Vaccinated
Individuals
To further evaluate the quality of the antibodies elicited after
vaccination, antibody affinity maturation as measured by SPR
were utilized to calculate the antibody dissociation off-rates for
individual sera in TIV- and LAIV-vaccinated subjects (Figure 3D).
Antibody off-rate constants, which describe the stability of antigen-
antibody complexes, were determined directly from serum sample
interaction with HA1 globular domain using SPR in the
dissociation phase as described [18]. The antibody dissociation
rates for the post-vaccination serum to the 2009-pH1N1-rHA1
averaged 7610
24 per second (ranged between 8.31610
23 and
2.56610
25) for the individuals following LAIV vaccination
(Figure 3D, open circles). In contrast, TIV vaccination resulted
in significantly lower anti-HA1 antibody dissociation rates or
higher antibody affinity (Figure 3D, filled circles) that averaged
8.76610
25 per second (ranged between 5.94610
24 and
2.92610
25). The mean antibody off-rates to 2009-pH1N1-HA1
were significantly different between TIV- and LAIV-vaccinated
individuals (p=0.0417) (Figure 3D).
Figure 1. Post-vaccination microneutralization titer distribu-
tion responses in vaccinated recruits based upon vaccine type.
doi:10.1371/journal.pone.0034581.g001
Table 1. Serologic responses in vaccinated recruits as measured by microneutralization assay, LAIV-vaccinated recruits (n=78).
Virus A/CA/7/2009 H1N1 A/Perth/16/2009 H3N2 A/CA/17/2011 H1N1
# Pre-vac. titer $40 (%) 17 (22%) 17 (22%) 8 (10%)
GMT Pre-vac. (95% CI) 10.5 (8.4–13.1) 12.5 (10.0–15.7) 7.8 (6.3–9.8)
# Post-vac. titer $40 (%) 40 (51%) 48 (62%) 25 (32%)
GMT post-vac. (95% CI) 30.9 (23.1–41.4) 47.2 (35.2–63.1) 17.7 (1323.7)
Seroconversion (%)
1 27 (35%) 37 (47%) 22 (28%)
Fold change (95% CI)
2 2.2 (1.7–2.9) 2.8 (2.1–3.7) 1.5 (1.1–2.0)
CI, confidence interval; GMT, geometric mean titer; LAIV, live attenuated influenza vaccine.
1Seroconversion is defined as a 4-fold increase in titer from pre-vaccine to post-vaccine titer.
2Fold change adjusted for pre-vaccine seroprotection levels.
doi:10.1371/journal.pone.0034581.t001
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To examine whether decreased serologic response from the A/
CA/7/2009 H1N1 vaccine strain to circulating pH1N1 viruses
isolated from recruits training in the southeastern United States in
early 2011 correlated with antigenic drift, the HA1 genes from
previous circulating and contemporaneous representative viruses
were sequenced and a phylogenetic tree constructed using the
neighbor-joining method (CLUSTAL W) of the MegAlign
program (Lasergene software suite; DNASTAR Inc., Madison,
WI) (Figure 4). Viruses in the tree are represented by amino acids
112 through 360 of the mature HA protein. Six circulating
subclades of 2009 pH1N1 (Groups 2–7) have been defined
previously http://www.ecdc.europa.eu/en/publications/Publica
tions/1110_SUR_Influenza_virus_characterization_August_Sept
ember%202011.pdf). Included in the phylogenic tree were 10
viruses isolated from Fort Jackson between January and March
2011, as well as representative viruses from three recruits at Fort
Benning, Cape May, and MCRD-PI collected concurrently.
These include Great Lakes RTC Jan-2011 (CY092872.1); Marine
Corps San Diego Jan-2011 (CY092880.1); Fort Jackson Jan 2011
(CY092888.1); Marine Corps Parris Island Jan-2011
(CY092896.1); Fort Benning Jan-2011 (CY092904.1); Mexico
InDRE1947 2011 (CY089391.1); and Mexico InDRE1945 2011
(CY089387.1). Viruses isolated during the January 2011 outbreak
at Fort Jackson are italicized. For reference, the tree contained
representative sequences from Fort Jackson and MCRD San
Diego collected during 2009, the vaccine strain, A/CA/7/2009,
and, finally, reference strains for the six circulating subclades of
2009 pH1N1 (Groups 2–7) that have been defined by specific
mutations. Phylogenetic analysis of viruses collected from recruits
during 2010–2011 demonstrated the presence of five of the six
previously characterized groups of 2009 pH1N1 viruses. Viruses
isolated between January and March from Fort Jackson recruits
vaccinated greater than 2 weeks clustered into Group 3 (Figure 4).
Relative to the vaccine strain, Group 3 viruses have four
mutations across the HA coding region sequenced, including
S183P. Interestingly, viruses collected from a Fort Jackson recruit
who had been vaccinated only 2 days prior to illness branched
into Group 2. Representative viruses from recruits in 2011
segregated into Groups 2, 6, and 7. These were detected
contemporaneously to the outbreak at Fort Jackson but were not
associated with the January outbreak and did not circulate
widely. Whole genome analysis of a representative strain (Fort
Jackson, January 2011) had seven mutations from the vaccine
strain (data not shown). Three of these mutations, P83S, S203T,
and I321V occurred very early during the evolution of the
pandemic virus and were fixed in the 2009 pH1N1 population.
Two of these mutations (A134T and S183P) are represented in
the Group 3 subclade.
Discussion
A survey to measure seroresponses to seasonal influenza vaccine
was conducted among military recruits at three RTCs in the
eastern and southeastern United States March 2011, following
intense transmission of pH1N1 in January, including one death,
among vaccinated recruits in South Carolina [16]. Serum
antibody studies indicated that (1) compared with LAIV, TIV
induced greater total serum antibodies, a more mature antibody
response as measured by isotype distribution, and antibodies with
greater affinity to HA1; (2) both LAIV and TIV induced
seroresponses against a circulating 2011 pH1N1 clade, but
responses were significantly lower than those against the vaccine
2009 pH1N1 strain; and (3) HA1 sequence analysis from
concurrently circulating pH1N1 strains in 2011 demonstrated
that a single clade with moderate drift from the pH1N1 vaccine
strain was responsible for the outbreak. We hypothesize that
increased pH1N1 infection among vaccinated recruits at Fort
Jackson in early 2011 resulted from antigenic mismatch between
the circulating pH1N1 strain and the pH1N1 vaccine strain.
Military recruits are homogeneously healthy and young. As a
result of crowding and a challenging training environment,
recruits experience higher respiratory disease rates than non-
recruits [19]. Vaccination reduces influenza rates in military
populations providing that the vaccine is a good antigenic match
Table 2. Serologic responses in vaccinated recruits as measured by microneutralization assay, TIV-vaccinated recruits (n=64).
Virus A/CA/7/2009 H1N1 A/Perth/16/2009 H3N2 A/CA/17/2011 H1N1
# Pre-vac. titer $40 (%) 10 (16%) 19 (30%) 5 (8%)
GMT pre-vac. (95% CI) 9.7 (7.6–12.4) 18.0 (14.0–23.0) 7.4 (5.8–9.5)
# Post-vac. titer$40 (%) 47 (73%) 62 (97%) 39 (61%)
GMT post-vac. (95% CI) 77.9 (56.5–107.4) 227.5 (165.0–313.8) 39.4 (28.5–54.3)
Seroconversion (%)
1 47 (73%) 54 (84%) 41 (64%)
Fold change (95% CI)
** 5.6 (4.1–7.6) 10.2 (7.6–13.8) 3.4 (2.5–4.7)
CI, confidence interval; GMT, geometric mean titer; TIV, trivalent inactivated influenza vaccine.
1Seroconversion is defined as a 4-fold increase in titer from pre-vaccine to post-vaccine titer.
**Fold-change adjusted for pre-vaccine seroprotection.
doi:10.1371/journal.pone.0034581.t002
Figure 2. Estimate of odds of a 4-fold conversion relative to
conversions against the H3N2 virus.
doi:10.1371/journal.pone.0034581.g002
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provide annual influenza vaccine effectiveness estimates [23].
Vaccine effectiveness is a function of the antigenic match between
circulating and vaccine influenza strains and host factors such as
previous influenza exposure, age, and immune status
[24,25,26,27,28,29,30]. Recruits generally receive multiple, simul-
taneous vaccinations during the first days at the RTC. These
factors must be taken into account when considering vaccine
response and effectiveness data.
Both TIV and LAIV have been shown to be effective in
children and adults, although multiple studies in children aged 6
months to 18 years have demonstrated that LAIV provides a
greater seroresponse than TIV [25,26,31]. While results in adults
have been mixed [32], TIV vaccination has generally been
reported as more effective than LAIV [33]. When vaccines are
staggered in a recruit setting rather than given simultaneously,
clinic visits for respiratory disease decreased by up to 20% [34]. A
large, cross-sectional study during the 2005–2006 influenza season
among military personnel determined that LAIV vaccination
provided greater protection from laboratory-confirmed influenza
than the TIV [15]. In non-recruits TIV provided greater
protection. Over the 2007–2008 influenza season, TIV was found
to be 50% more effective than LAIV in adult populations [24]. A
monovalent LAIV pH1N1 vaccine showed differing vaccine
efficacy based upon age groups when influenza-like symptoms
were considered [35]. In our study, geographic differences (vaccine
type and circulating strain) and ongoing adenovirus transmission
at the RTC precluded a clear comparison between vaccine types
based on symptom data alone.
Our results show differential immune response between LAIV
and TIV consistent with previous reports. The quantitative and
qualitative robustness of T and B cell memory responses to viral
antigens are mediated by previous exposure and/or vaccination.
Recently, a study in children ages 6–35 months found that LAIV
Figure 3. Affinity measurements isotyping and total anti-HA1 binding antibody in human sera following immunization. (A–B)
Correlation between in vitro MN titers and rHA1 binding in human sera following immunization with H1N1 vaccine in TIV and LAIV
groups. Steady-state equilibrium analysis of the binding of vaccine serum IgG to properly folded functional HA1 oligomers was measured using
surface plasmon resonance (SPR). Ten-fold diluted post-H1N1 vaccination sera from vaccine groups (LAIV in A, TIV in B) were injected simultaneously
onto HA1 immobilized on a sensor chip, free of peptide. Binding was recorded in resonance units (RU) values. The maximum RU values for HA1
binding by serum antibodies obtained from vaccinated individuals with either LIAV (A) or TIV (B) vaccination is shown on the Y-axis. The MN titer is
expressed as end-point neutralizing antibody titer of post-H1N1 vaccine sera and is depicted on the X-axis. (C) The isotype of serum antibodies
bound to rHA1 for the two vaccine groups. Data shown are the means for serum from two independent experiments. (D) Antibody avidity
measurements in polyclonal serum by off-rate constants using SPR. Antibody off-rate constants, which describe the stability of the complex
were determined directly from the serum/plasma sample interaction with rHA1 protein using SPR in the dissociation phase. For accurate
measurements, parallel lines in the dissociation phase for the 10-fold and 100-fold dilution for each post-vaccination human sera were required. The
off-rate constants were determined from two independent SPR runs. SPR analysis of post-vaccinated human sera with LAIV (left) or TIV (right) from
the vaccine trial was performed with properly folded H1N1pdm09 HA1 (A/CA/7/2009) [60]. Serum antibody off-rate constants for vaccinees (each
symbol is one individual) were plotted. Correlation statistics of affinity measurement and off-rate constants of sera binding to rHA1 between LAIV and
TIV vaccinees were statistically significant with p,0.05 (T-test).
doi:10.1371/journal.pone.0034581.g003
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conserved influenza peptides than TIV [36]. He et al. determined
that the phenotypic changes of influenza-specific CD8
+ differed
significantly between LAIV and TIV depending on the age of the
vaccinee. The authors of this study speculated that the route of
vaccination influenced antigenic presentation [37]. A prospective,
randomized trial to compare the safety and efficacy of LAIV and
TIV in adults in South Africa found that those $60 years old had
better T cell responses to LAIV but superior humoral immune
responses to TIV [38]. In our work, TIV vaccinated recruits
exhibited increased antibody class switching (IgM-.IgG) and
affinity maturation to 2009 pH1N1 compared with LAIV-
vaccinated individuals. While serum antibody HI titers are a
correlate of protection, modest antibody titers following LAIV
vaccination do not necessarily indicate a failure of protection [39].
However, the generation of anti-influenza antibodies with
increased affinity among the TIV vaccinees likely allowed more
effective clearance of infecting influenza viruses. Differential
presentation in the two vaccines of similar antigens might have
driven alternate immunoglobulin class switching and maturation
routes. SPR on post-vaccination antibody binding to HA1 peptide
demonstrated that TIV vaccination elicited a more mature
response and that serum antibody binding antibodies to rHA1
after vaccination strongly correlated with the MN titers against the
2009 pH1N1 vaccine strain. As previously demonstrated in ferrets
[40,41] and humans [42], these findings suggested that rHA1
oligomer-binding antibodies are involved in virus neutralization.
Our results provided evidence for modest antigenic drift in
pH1N1 viruses from the southeastern United States in 2011.
There were significant differences in vaccine-induced serum
antibody neutralization in the vaccine strain 2009 pH1N1 as
compared to the circulating 2011 pH1N1. Contemporaneously
collected viruses from nationwide surveillance were rooted against
the vaccine and other circulating strains to infer divergence in the
HA surface protein.
Recruits arrive at the RTCs from regions across the United
States, resulting in the potential seeding of diverse viruses. This
was demonstrated in our study as isolates from four of six
subclades (Groups 2, 3, 6, and 7) were found at Fort Jackson
during the first 2 months of 2011. Interestingly, only one of these,
Group 3, circulated widely during the outbreak in January 2011.
In the spring of 2009, distinct spatial heterogeneity existed
within pH1N1 viruses, resulting in strong regional founder effects.
During this first wave, multiple phylogenetically distinct pH1N1
clades emerged globally [43]. However, by the end of the second
wave at the end of 2009, extensive viral migration and mixing
resulted in the emergence of a single dominate viral lineage, in
New York State [44]. The international profile of New York likely
contributed to the seeding of this virus to regions across the world
over the next 12–18 months [45], although other clades continue
to circulate.
Analysis of the HA genome elucidated a number of mutations in
2011 pH1N1 viruses. The S183P mutation in the Fort Jackson
viruses has been shown in vitro to inhibit the binding of the DFA
monoclonal antibody from the WHO Influenza Detection Kit
distributed in 2011 [46]. This mutation has been found in the
1918 pandemic influenza virus and shown to have increased
virulence in mouse models [47]. The reversion mutation S84N,
Figure 4. Phylogenetic analysis of the hemagglutinin (HA) gene of influenza pH1N1 isolates. The phylogenetic tree was constructed
using the neighbor-joining method (CLUSTAL W method) of the MegAlign program (Lasergene software suite, DNASTAR Inc., Madison, WI). The tree
represents amino acids 111 through 360 of the mature HA protein. Reference strains for the six circulating subclades (2–7) are shown in bold text,
with their defining mutations shown to the right. The vaccine strain, A/CA/7/2009, is shown in bold and italicized. Isolates collected by NHRC from
recruits who had been vaccinated greater than 14 days are italicized. Strains from the same geographical location and time of collection from the
GISAID database are included in the tree as well as two samples collected from the same recruit training sites in 2009. The scale indicates the distance
created by a one amino-acid difference between sequences. The number of amino acid changes between subclades is denoted by a delta symbol (D).
doi:10.1371/journal.pone.0034581.g004
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decreased antigenic responses [48]. These studies provide possible
mechanisms underlying immune evasion in the pH1N1 viruses
from the Fort Jackson region in 2011.
The outbreak of pH1N1 in vaccinated recruits occurred during
a time when influenza A/H3N2 and B viruses and multiple
subclades of A/pH1N1 circulated in the Fort Jackson. However,
only one (Group 3) was evident during the outbreak. This
circulating virus had important HA mutations that mediate
antibody binding. Moderate antigenic divergence between circu-
lating and vaccine influenza strains likely contributed to the
outbreak of pH1N1 among recruits at Fort Jackson in the early
weeks of 2011.
At Fort Jackson, the protective threshold was breached in LAIV
vaccinees infected with antigenically divergent subclade 3 pH1N1
viruses. Increased TIV vaccination in the Fort Jackson recruit
population could induce higher antibody titers and protective
immunity. We speculate that TIV vaccination would increase
overall vaccine effectiveness, thereby providing a herd immunity
effect across the population.
The effectiveness of seasonal influenza vaccines varies by
season. The risk of periodic influenza epidemics as a result of
antigenic drift may best be ameliorated through the development
of a universal influenza vaccine [49] and/or therapeutics that
address issues of antiviral resistance, such as multi-drug combina-
tional therapy [50]. Our work accentuates the need for intense
surveillance tied to timely virus characterization and agile
production of vaccines and therapeutics in response to ever-
adapting influenza viruses.
Materials and Methods
Influenza Vaccination
Recruits undergoing basic combat training at Fort Jackson were
vaccinated intranasally prior to the first week of training with the
LAIV FluMist (MedImmune, LLC, Gaithersburg, MD) per
manufacturer’s instructions. Each 0.2 prefilled dose contained
10
6.5–7.5 fluorescent focus units of live attenuated influenza virus
reassortants of each of the three strains recommended by WHO
for the 2010–2011 season: A/CA/7/2009 (H1N1), A/Perth/16/
2009 (H3N2), and B/Brisbane/60/2008. Prior to the first week of
recruit training at MCRD-PI, female recruits were vaccinated with
the TIV influenza vaccine AFLURIA (CSL Biotherapies, King of
Prussia, PA) per manufacturer’s instructions. The AFLURIA
influenza vaccine was standardized for the 2010–2011 influenza
season and formulated to contain 45 mcg HA per 0.5 mL dose in
the recommended ratio of 15 mcg HA for each of the three
influenza strains recommended for the 2010–2011 Northern
Hemisphere influenza season. Male recruits at MCRD-PI were
vaccinated with the MedImmune LAIV FluMist, as previously
described. Recruits at Cape May were vaccinated with the
Fluzone TIV (Sanofi Pasteur, Inc., Swiftwater, PA) per manufac-
turer’s instructions. Each 0.5-mL dose of Fluzone contained a total
of 45 mcg of influenza virus HA equally distributed among the
three components of the 2010–2011 influenza vaccine.
Ethics Statement
The proposal for serologic draw was reviewed and approved as
a public health response, non-research activity by the U.S. Army
Public Health Command Public Health Review Board, the
Institutional Review Board (IRB) at the Naval Health Research
Center (NHRC), and the Armed Forces Health Surveillance
Center. Participation for blood draw was voluntary, and consent
obtained verbally per observation by local investigators. Per the
proposal approved by the NHRC IRB, all samples were de-
identified. Concurrently, throat and nasal swabs were collected
under ongoing NHRC protocol NHRC.1999.0002 approved by
the NHRC IRB from recruits who presented with an FRI and
consented, in writing, to be swabbed. This project has been
conducted in compliance with all applicable federal regulations
governing the protection of human subjects in research.
Sample Collection
The serosurvey was conducted by systematically enrolling
recruits 4–5 week’s post-influenza vaccination. Recruits completed
a short case report form (CRF) that included information on
previous vaccination, age, sex, and signs and symptoms. Influenza
vaccination history (date, vaccine type) was abstracted from
medical records at each training center. Blood was drawn in 10-ml
serum separator tubes (BD Biosciences, Franklin Lakes, NJ) and
allowed to clot for 30 minutes. Tubes were centrifuged for
10 minutes, and then frozen at between 220uC and 280uC prior
to shipment to NHRC for analysis. Baseline sera were provided
from the DoDSR, which maintains serum specimens collected
from service members for periodic HIV testing and operationally
required pre- and post-deployment blood draws [51]. Baseline
samples were shipped to NHRC on dry ice.
Concurrently, throat and nasal swabs were collected from
recruits who presented with an FRI. At RTCs, denominator data
for all FRIs are collected and 10–20 patients are randomly selected
for sampling each week throughout the year. FRI was defined by
fever (.38.0uC), sore throat, and/or cough. Enrollees provided a
CRF containing demographic and medical history data. Swabs
were collected in universal transport medium (Copan Diagnostics,
Inc., Murrieta, CA), stored at 4uC, and then shipped to NHRC for
real-time RT-PCR (rRT-PCR), viral isolation, and genetic
characterization.
Virus Propagation and Microneutralization Assay
Influenza viruses were propagated in MDCK cells to high titer,
and TCID50 determined using the Reed-Muench method.
Negative and positive control sera for A/CA/7/2009 (2009
pH1N1) and A/Perth/16/2009 (H3N2) were obtained from the
2010–2011 WHO Influenza Reagent Kit. Positive control ferret
antisera for A/CA/17/2011 (2011 pH1N1) were provided by
CDC, Atlanta, Georgia. All control sera were treated with
receptor-destroying enzyme (RDE), heat inactivated at 56uC for
30 minutes, and then diluted to a 1:10 concentration. Serum
antibody MN assays were performed according to described
procedures [52,53]_ENREF_25. Briefly, serum was inactivated at
56uC for 30 minutes and then 2-fold serum dilutions made in a
range of 1:5 to 1:640. Positive control serum was serially diluted to
1:1280; negative control was initially undiluted and then serially
diluted 2-fold. After sera (both samples and controls) were serially
diluted, 50 ml of working dilution (200 TCID50/50 ml) was added
to the wells. Cell controls were included in each plate for data
analysis. A/CA/7/2009 H1N1 (2009 pH1N1), A/Perth/16/2009
H3N2 (H3N2), and A/CA/17/2011 H1N1 (2011 pH1N1) were
propagated in MDCK cells. After a 1-hour incubation at 37uCi n
5% CO2, 30 ml of virus growth medium (Dulbecco’s Modified
Eagle’s Medium containing 0.25% bovine serum albumin, 25 mM
HEPES buffer, 100 U/ml penicillin, 100 mg/ml streptomycin, and
3 mg/ml TPCK-trypsin) was added and flasks incubated for
16 hours at 37uCi n5 %C O 2. MDCK flasks at 75–95%
confluence were harvested and cell suspensions combined and
centrifuged at 1500 rpm for 5 minutes. The culture supernatant
was replaced with 15 ml of fresh virus growth medium and the
cultures incubated 18–24 hours or until cells exhibited approxi-
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activity of at least 32 hemagglutination units using a 0.5%
suspension of turkey erythrocytes. Following an overnight
incubation, plates were decanted and washed once with 200 ml
sterile PBS. Anti-influenza A nucleoprotein was added to fixed
plates at a 1:1000 dilution and incubated at room temperature for
1 hour. After washing, goat anti-IgG conjugated horseradish
peroxidase at a 1:2000 dilution was added for 1 hour. Absorbance
in washed and blocked plates was read at 490 nm wavelength. MN
titers were expressed as reciprocal of the highest dilution of serum
that gave 50% neutralization. For calculation of geometric mean
titer (GMT) estimates, a titer of ,10 was assigned a value of 5.
Seroprotection was determined by MN as the percentage of serum
titers $40. Seroconversion rates were defined as the percentage of
vaccine recipients whose serum MN titers increased by at least 4-
fold after vaccination. A p value ,0.05 was considered significant.
Hemagglutination Inhibition Assay
The HI assays were performed according to the WHO protocol
for serological diagnosis of influenza virus infection using
standardized 0.75% guinea pig red blood cells (GPRBC). Serum
samples were treated with RDEs overnight at 37uC, and heat
inactivated the following day. Serum samples, including negative
and positive controls, were initially diluted 1:10 with PBS and then
serially diluted 2-fold from 1:10 to 1:1280. Influenza viruses were
adjusted to contain 4 HA units/25 ml and added to wells. GPRBC
were added to all wells, and incubated at room temperature for
1 hour. Antibody titer for the particular virus was determined as
the highest serum dilution showing complete inhibition for each
serum sample tested.
Statistical Analyses of MN and HI Data
Differences between groups were examined for statistical
significance using Student’s t-test. An unadjusted p value ,0.05
was considered significant. For all MN and HI testing, each
sample was tested in duplicate with the requirement that both
results must agree to within one dilution. A titer of ,10 was
assigned a value of 5 for calculation purposes. GMTs of the
replicates were used to estimate pre- and post-vaccination titers
and the associated fold change.
Population pre- and post-vaccination GMTs were calculated for
the three viruses (2009 pH1N1, 2011 pH1N1, H3N2) for each
vaccination type (TIV and LAIV). Additionally, adjusted geometric
mean fold change was estimated for each virus and vaccination
type, after adjustment for starting titer as previously described [54].
Confidence intervals of all means were calculated using the least
squares method, allowing us to evaluate the significance of the
differences between vaccine type and virus strains.
Linear regression was used to evaluate differences in the
geometric increases in HI and MN titers for different viruses and
different types of vaccination. Logistic regression allowed differ-
ences in the odds of a 4-fold rise in titer to be evaluated between
vaccination types and virus strains while adjusting for pre-vaccine
levels. For this comparison, the rate of 4-fold rise in titer against
H3N2 was used as a reference.
Binding to rHA1 Proteins and Antibody Isotyping by
Surface Plasmon Resonance
Steady-state equilibrium binding of post-immunization 2009
pH1N1 human vaccine sera was monitored at 25uC using a
ProteOn SPR biosensor (Bio-Rad Laboratories, Inc., Hercules,
CA), as previously described [55]. The 2009 pH1N1-rHA1
proteins were coupled to a GLC sensor chip with amine at 500
resonance units (RU) in the test flow cells. Samples of 60 mlo f
freshly prepared sera at 10-fold dilutions were injected at a flow
rate of 30 ml/min (120-second contact time) for association, and
dissociation was performed over a 600-second interval (at a flow
rate of 30 ml/min). Responses from the protein surface were
corrected for the response from a mock surface and for responses
from a separate, buffer-only injection. MAb 2D7 (anti-CCR5) was
used as a negative control in these experiments. Binding kinetics
for the selected human vaccine sera and data analyses were
calculated using Bio-Rad ProteOn manager software (version 3).
For isotyping of the human serum antibodies bound to the rHA1
coupled chip, anti-human isotyping antibodies for human IgA,
IgG, and IgM were injected onto the chip following the human
sera interaction with coupled antigen on the GLC chip.
Affinity Measurements by Surface Plasmon Resonance
Steady-state equilibrium binding of pre- and post-H1N1 human
vaccine sera was monitored at 25uC using a ProteOn SPR
biosensor (Bio-Rad). Antibody off-rate constants, which describe
the stability of the complex (i.e., the fraction of complexes
decaying per second), were determined directly from plasma
sample interaction with properly folded, pH1N1-functional HA1
globular domain and HA2 stalk domain proteins [40] during the
dissociation phase. They were calculated using the Bio-Rad
ProteOn manager software for the heterogeneous sample model,
as previously described [56]. To improve measurements, the off-
rate constants were determined from two independent SPR runs.
Differences between groups were examined for statistical signifi-
cance using Student’s t-test. An unadjusted p value ,0.05 was
considered significant.
Real-Time Reverse Transcriptase Polymerase Chain
Reaction Amplification
Ribonucleic acid was extracted from combined throat and nasal
swabs using the QIAamp RNA Mini Kit (Qiagen, Valencia, CA)
following manufacturer’s instruction. rRT-PCR assays were used
to detect influenza A and B viruses and to subtype A viruses as
either H1, pH1, or H3, as previously described [57]. One-step
rRT-PCR was performed in a final volume of 25 mL, which
contained 5 ml of extracted RNA, 12.5 mL of buffer mix, and
0.5 mL SuperScript III Platinum Taq enzyme (Invitrogen,
Carlsbad, CA), 0.8 mM for each primer, and 0.2 mM of probe.
A 7500 Fast DX Real-Time PCR System (Applied Biosystems
Inc., Foster City, CA) was used for rRT-PCR reactions. The
thermocycling parameters for targets consisted of 50uC for
30 minutes, 95uC for 2 minutes, and 45 cycles with 95uC for
15 seconds, and 55uC for 30 seconds.
Viral Isolation
Virus isolation was performed in MDCK cells or R-Mix Too
Shell Vials (Diagnostic Hybrids, Inc. [DHI], Athens OH). In shell
vials, medium was aspirated and 1 mL of R-Mix Refeed media
(DHI) containing 100 units/mL penicillin, 100 ug/mL strepto-
mycin, and trypsin (bovine origin) at 1.33 ug/mL, was added.
Vials were inoculated with 0.2 mL of swab extract and then
centrifuged at 2100 rpm (RT) for 1 hour. After centrifugation,
vials were incubated for 48 hours, washed with sterile PBS twice,
and fixed in acetone. Immunofluorescence assays were conducted
using D3 Ultra DFA Respiratory Virus Screening Reagent (DHI).
Viruses were replicated and amplified in MDCK flasks, at 80–
90% confluency. Upon CPE approximately 75% of the susceptible
cells were harvested and centrifuged at 2000 rpm, at 4uC, for
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obtain 200 TCID50/50 mL.
HA1 Sequencing
Primers for sequencing influenza HA protein were provided by
the CDC and are available upon request. An initial amplicon was
produced with a paired primer set in a 25 uL aqueous reaction
containing 16 Colorless GoTaq Flexi Reaction Buffer (Promega
Corporation, Madison, WI), 0.2 mM each dNTP (Promega),
1.5 mM MgCl2 (Promega), 0.6 uM concentration of each primer,
0.5 U GoTaq DNA Polymerase (Promega), and 5 uL of template.
Products were mixed 5:1 with loading dye (Sigma-Aldrich, St.
Louis, MO) and run for 90 min at 125 V on 2% agarose (Bio-Rad,
Hercules, CA) gels with ethidium bromide (Sigma-Aldrich).
Cycling conditions were an initial 60 seconds at 96uC followed
by 25 cycles of 10 seconds, 96uC; 5 seconds, 50uC; 4 minutes,
60uC, and a final hold at 40uC. Gels were visualized in an
ultraviolet light box. Amplicons were excised and purified using
the QIAquick gel extraction kit (Qiagen) according to manufac-
turer’s instructions. Amplicons were then used as template in
sequencing reactions containing 16 BigDye Terminator v3.1
Buffer (Applied Biosystems, Foster City, CA), 1 uL of BigDye
Terminator Ready Reaction Mix v. 3.1, 0.2 uM forward or
reverse primer, and 5 uL of amplicon in a 20 uL aqueous
reaction. Reactions were performed on an iCycler PCR machine
(Bio-Rad). Sequencing products were purified using Performa
DTR Gel Filtration Cartridges (Edge BioSystems, Gaithersburg,
MD) and sequenced on a 3130 Genetic Analyzer (Applied
Biosystems).
Whole Genome Analysis
Sequencing, genome assembly, and closure reactions were
performed as described [58]. Briefly, influenza multiplex RT-PCR
products were randomly amplified and prepared for next-
generation sequencing using a sequence-independent single-
primer amplification (SISPA) method as previously described
[59]. Amplified viral DNA was denatured in the presence of
dimethyl sulfoxide and a chimeric oligonucleotide containing a
known bar code 22-nt sequence followed by a 39 random
hexamer. A Klenow reaction was prepared with the denatured
DNA template. The resulting cDNA was randomly amplified by
PCR using AccuPrime Taq at 35 cycles (denaturation: 30 seconds,
94uC; annealing: 30 seconds, 55uC; extension: 48 seconds, 68uC).
PCRs were conducted using primers corresponding to the known
22-nt bar-code sequence from the oligonucleotide utilized in the
previous Klenow step. SISPA products were normalized and
pooled into a single reaction that was subsequently purified. This
sample was gel purified to select for SISPA products ,800 bp in
size. Identical aliquots were then submitted for sequencing with
both 454 (Clinical Genomics, Australia) and Illumina (DNAS-
TAR, Inc., Madison, WI) sequencing technologies.
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